Efficacy and Safety of Primary Radiotherapy in Combination with EGFR-TKIs for Non-Small Cell Lung Cancer Harboring EGFR Mutation

作     者：Dongxu Ao Meng Wang Jinyuan Xie Yang Zhang Xinran Zhang Ya Shu Chenshi Lin Qingqing Ye Dongxu Ao;Meng Wang;Jinyuan Xie;Yang Zhang;Xinran Zhang;Ya Shu;Chenshi Lin;Qingqing Ye

作者机构：Department of Oncology The First Affiliated Hospital of Yangtze University Jingzhou China Department of Joint Surgery and Sports Medicine Jingmen Central Hospital Jingmen China Department of Breast Surgery The First Affiliated Hospital of Yangtze University Jingzhou China 

出 版 物：《Journal of Biosciences and Medicines》 (生物科学与医学（英文）)

年 卷 期：2024年第12卷第9期

页      面：142-154页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Non-Small Cell Lung Cancer Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Radiotherapy 

摘      要：Objective: To evaluate the efficacy and safety of EGFR-TKI with the radiotherapy in EGFR mutant metastatic NSCLC. Methods: Retrospective analysis of 72 patients with stage IV lung cancer with EGFR-sensitive mutation. Patients in the A group were treated with the first-generation EGFR-TKI (Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor) combined with radiotherapy for primary tumors (34 cases). The B group was treated with the first-generation EGFR-TKI alone until the disease progressed (38 cases). PFS, OS, pulmonary infection and hematological toxicity during treatment were commented in both groups. Results: The objective remission rate was 47.1% (16/34) in the A group and 21.1% (8/38) in the B group. There was a significant difference between the two groups. There was no significant difference in hematological toxicity between the A group and the B group. There were 10 patients (29.4%) with degree II pulmonary infection in the A group and 3 patients (7.9%) in the B group. The difference between the two groups was statistically significant, suggesting that the incidence of pneumonia in the A group was higher than that in the B group. The median PFS (Progression-Free Survival)) and OS (Overall Survival) of the A group were significantly longer than those of the B group (16.5 months vs 9 months) and the median OS (36 months vs 19 months). The PFS and OS in the A group were significantly longer than those in the B group. Conclusion: EGFR-TKI combined with primary radiotherapy can significantly prolong the drug resistance time of EGFR mutant metastatic NSCLC.